Pharmaceutical stocks are seen as resilient during economic downturns due to their steady demand, making them attractive options for buy-and-hold investors despite ongoing drug pricing concerns.
Eli Lilly’s stock has surged 1,269% over the last decade, signaling strong growth potential as it leads the pharmaceutical industry and is projected to reach a $1 trillion valuation.
Lilly commits to expanding access to medicines globally while aiming for carbon neutrality by 2030, reflecting its dedication to responsible and sustainable growth in the pharmaceutical sector.
While Eli Lilly's dividend yield is only at 0.6%, it has consistently increased its payout for ten years, showcasing the company’s commitment to shareholder returns in a growth-driven market.
Collection
[
|
...
]